88 Chapter 4 analysis, we added the three N markers HV, NfL and GFAP simultaneously in a model in addition to Aβ and p-tau, since these biomarkers added predictive value in model 4. In this model, only HV remained significantly associated with clinical progression to MCI or dementia (HR 1.45 (SE 1.01 – 2.09)). The associations for NfL (0.94 (0.56 – 1.59)) and GFAP (1.40 (0.86 – 2.29)) were attenuated (n=258 due to varying availability rates for N biomarkers). Results of the analyses for complete cases only (n=256) were overall similar, although not all associations survived FDR correction (eTable 1). Table 2. Risk of mild cognitive impairment or dementia for continuous N biomarkers Biomarker n Model 1 Model 2 Model 3 Model 4 T-tau 401 2.32 (1.86 - 2.88) a,b 2.12 (1.67 - 2.70)a,b 1.74 (1.36 - 2.23)a,b Aβ 1.98 (1.50 - 2.63)a,b P-tau MTA 364 1.34 (1.06 - 1.69)a,b 1.02 (0.78 - 1.34) 0.97 (0.74 - 1.28) 1.00 (0.76 - 1.33) Aβ 2.43 (1.79 - 3.31)a,b 2.18 (1.60 - 2.96)a,b P-tau 1.42 (1.07 - 1.89)a,b HV 361 1.55 (1.17 - 2.07)a,b 1.36 (0.99 - 1.87) 1.43 (1.06 - 1.95)a,b 1.52 (1.11 - 2.09)a,b Aβ 2.58 (1.88 - 3.54)a,b 2.25 (1.65 - 3.07)a,b P-tau 1.49 (1.14 - 1.94)a,b NfL 296 1.92 (1.51 - 2.46)a,b 1.61 (1.18 - 2.21)a,b 1.42 (1.00 - 2.01) 1.51 (1.05 - 2.17)a,b Aβ 2.24 1.59 - 3.15)a,b 1.96 (1.41 - 2.72)a,b

RkJQdWJsaXNoZXIy MjY0ODMw